Watching Novavax Inc. (NVAX) For Insider Activity

Novavax Inc. (NASDAQ:NVAX) traded with a subtraction of -$3.57 to $108.81 on Friday, a downside of -3.18 percent. An average of 5,319,113 shares of common stock have been traded in the last five days. There was a fall of -$18.09 in the past week, and it reached a new high 9 times over the past 12 months. The last 20 days have seen an average of 7,188,363 shares traded, while the 50-day average volume stands at 5,884,811.

NVAX stock has decreased by -33.28% in the last month. The company shares reached their 1-month lowest point of $101.10 on 01/14/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $111.25 and a high of $331.68 in 52 weeks. It has reached a new high 1 time so far this year and lost -21.45% or -$34.46 in price. In spite of this, the price is down -67.19% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Insider Transactions

11 days have passed since Novavax Inc. (NVAX) last reported insider trading activity. Herrmann John A III, who is EVP, Chief Legal Officer, most recently acquired $5,000 shares at $140.91 per share on Jan 03. In this transaction, the insider spent $704,534. Director, YOUNG JAMES F, disposed of 3,750 shares at a price of $144.16 on Dec 31. The insider now owns more than $540,601 worth of shares. Prior to that, EVP, Chief Legal Officer Herrmann John A III went on to Sale 5,000 shares at $230.00 each on Dec 20. An amount of $1,150,000 was transacted.

Valuation Metrics

Novavax Inc. (NVAX) has a trailing price-to-earnings (P/E) ratio of 32.40 for the broader industry and 27.85 for the sector. The stock’s beta is 1.21. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 6.77, the price-to-book (PB) ratio at 18.21, and the price-to-cash flow ratio at 17.96.

The quick ratio of Novavax Inc. for the three months ended September 29 was 1.20, and the current ratio was 1.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.70 and a total debt to equity ratio of 0.93 for the quarter ending September 29. Novavax Inc.’s EBITDA margin for the year ending September 29 is -86.03%, while its operating margin for the same period stands at -86.80%. Its gross profit as reported stood at $892.32 million compared to revenue of $475.6 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Novavax Inc.’s return on assets was -45.20%. For the broader industry, ROE averaged -38.78 over the past year.

Earnings Surprise

In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$322.43 million in the quarter, while revenues of -$352.32 million were grew 94.57%. The analyst consensus anticipated Novavax Inc.’s latest quarter earnings to come in at -$3.91 per share, but it turned out to be -$4.31, a -10.20% surprise. For the quarter, EBITDA amounted to -$302.88 million. Shareholders own equity worth $75.61 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Novavax Inc. (NVAX) price momentum. RSI 9-day as of the close on 13 January was 24.75%, suggesting the stock is oversold, with historical volatility in this time frame at 99.20%.

As of today, NVAX’s price is $123.37 -14.28% or -$18.09 from its 5-day moving average. NVAX is currently trading -44.28% lower than its 20-day SMA and -53.39% lower than its 100-day SMA. However, the stock’s current price level is -44.36% below the SMA50 and -41.55% below the SMA200.

The stochastic %K and %D were 11.85% and 17.33%, respectively, and the average true range (ATR) was 14.21. With the 14-day stochastic at 10.03% and the average true range at 15.23, the RSI (14) stands at 31.09%. The stock has reached -8.05 on the 9-day MACD Oscillator while the 14-day reading was at -16.93.

Analyst Ratings

JP Morgan downgraded Novavax Inc. (NASDAQ: NVAX) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as an Overweight. The consensus rating for Novavax Inc. (NVAX) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell NVAX, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.

What is NVAX’s price target for the next 12 months?

Analysts predict a range of price targets between $209.00 and $315.00, with a median target of $282.00. Taking a look at these predictions, the average price target given by analysts for Novavax Inc. (NVAX) stock is $270.00.


Please enter your comment!
Please enter your name here


Hot Topics

Related Articles